GT Biopharma, Inc. (NASDAQ: GTBP) reported a net loss of $28.4 million for the year ended December 31, 2025, a $15.2 million increase over the prior year. The larger loss is largely attributable to a non‑cash fair‑value adjustment related to the company’s Series L preferred stock, which was recorded as a loss in the income statement but does not affect cash flow.
The company’s cash and cash equivalents stood at approximately $7 million as of December 31, 2025, with an unaudited pro‑forma cash balance of about $9 million as of January 31, 2026. Management indicated that this balance should provide sufficient runway to fund operations through the fourth quarter of 2026, assuming no additional financing is required. However, both management and auditors have expressed substantial doubt about the company’s ability to continue as a going concern, underscoring the fragility of the cash position.
Research and development expenses for the full year 2025 were approximately $3.5 million, down from $5.8 million in 2024—a decline of roughly 40%. The reduction reflects a scaling back of certain clinical trial activities and a focus on cost‑efficient development of the company’s TriKE® platform candidates.
Selling, general and administrative costs were about $8.5 million in 2025, essentially flat compared with $8.3 million in 2024. The lack of a significant decrease indicates that the company has not been able to achieve the cost‑control gains it may have anticipated in the first half of the year.
GT Biopharma announced a restatement of its financial statements for the quarters ended June 30, 2025, and September 30, 2025. The restatement was prompted by an accounting error that classified certain greenshoe rights as equity rather than a liability, which increased the company’s liabilities and accumulated deficit for those periods.
The company has a $20 million committed equity facility at a 7% discount to VWAP, which is intended to support ongoing operations and bridge the cash runway gap identified in the going‑concern assessment.
In its commentary, Executive Chairman and CEO Michael Breen noted that 2026 will bring significant milestones, including the initiation of the first clinical trial with GTB‑5550. He added that GTB‑3650 has shown an excellent safety profile to date and that higher dose cohorts will better reflect potential efficacy thresholds. He emphasized that the company’s cash runway extends through Q4 2026 and that the next update will be provided in the third quarter of 2026.
The company’s financial position remains precarious. The combination of a substantial net loss, a modest cash balance, and a restated balance sheet highlights the need for additional financing to avoid a liquidity crisis. Investors should weigh the ongoing pipeline progress against the risks associated with the company’s limited cash resources and the uncertainty surrounding future capital raises.
The results underscore the challenges faced by a clinical‑stage biopharmaceutical company that has yet to generate product revenue. While the company continues to advance its TriKE® platform candidates, the financial metrics and the going‑concern warning signal that the company’s survival will depend on securing new capital and maintaining disciplined spending.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.